Daewoong Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014

Published: Mar, 2014 | Pages: 67 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Daewoong Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Daewoong Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the Daewoong Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Daewoong Pharmaceutical Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Daewoong Pharmaceutical Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Daewoong Pharmaceutical Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Daewoong Pharmaceutical Co., Ltd.'s pipeline products

Reasons to buy

- Evaluate Daewoong Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Daewoong Pharmaceutical Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Daewoong Pharmaceutical Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Daewoong Pharmaceutical Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Daewoong Pharmaceutical Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Daewoong Pharmaceutical Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Daewoong Pharmaceutical Co., Ltd. Snapshot 7
Daewoong Pharmaceutical Co., Ltd. Overview 7
Key Information 7
Key Facts 7
Daewoong Pharmaceutical Co., Ltd. - Research and Development Overview 8
Key Therapeutic Areas 8
Daewoong Pharmaceutical Co., Ltd. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Combination Treatment Modalities 13
Pipeline Products - Partnered Products 14
Partnered Products/Combination Treatment Modalities 15
Daewoong Pharmaceutical Co., Ltd. - Pipeline Products Glance 16
Daewoong Pharmaceutical Co., Ltd. - Late Stage Pipeline Products 16
Pre-Registration Products/Combination Treatment Modalities 16
Phase III Products/Combination Treatment Modalities 17
Daewoong Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products 18
Phase II Products/Combination Treatment Modalities 18
Phase I Products/Combination Treatment Modalities 19
Daewoong Pharmaceutical Co., Ltd. - Early Stage Pipeline Products 20
Preclinical Products/Combination Treatment Modalities 20
Discovery Products/Combination Treatment Modalities 21
Daewoong Pharmaceutical Co., Ltd. - Unknown Stage Pipeline Products 22
Unknown Products/Combination Treatment Modalities 22
Daewoong Pharmaceutical Co., Ltd. - Drug Profiles 23
aclidinium bromide 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
(rosuvastatin calcium + olmesartan medoxomil) 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
DWJ-1261 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
IMD-4 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
nepidermin 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
onabotulinumtoxinA biosimilar 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
DWP-05195 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
DWJ-204 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
DWP-09031 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
DWP-10292 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
DWP-418 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
etanercept biosimilar 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
DWJ-1308 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
DWJ-1325 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
DWJ-206 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
DWJ-208 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
DWJ-800 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
DWP-451 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
DWP-455 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
DWJ-1330 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
DWJ-1340 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
DWJ-1341 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
DWJ-205 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
DWJ-209 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Undisclosed Program 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
(aclidinium bromide + formoterol fumarate) 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Daewoong Pharmaceutical Co., Ltd. - Pipeline Analysis 51
Daewoong Pharmaceutical Co., Ltd. - Pipeline Products by Target 51
Daewoong Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration 53
Daewoong Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type 54
Daewoong Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action 55
Daewoong Pharmaceutical Co., Ltd. - Recent Pipeline Updates 57
Daewoong Pharmaceutical Co., Ltd. - Dormant Projects 62
Daewoong Pharmaceutical Co., Ltd. - Discontinued Pipeline Products 63
Discontinued Pipeline Product Profiles 63
lagociclovir 63
Daewoong Pharmaceutical Co., Ltd. - Company Statement 64
Daewoong Pharmaceutical Co., Ltd. - Locations And Subsidiaries 65
Head Office 65
Other Locations & Subsidiaries 65
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 67
Disclaimer 67

List of Tables
Daewoong Pharmaceutical Co., Ltd., Key Information 7
Daewoong Pharmaceutical Co., Ltd., Key Facts 7
Daewoong Pharmaceutical Co., Ltd. - Pipeline by Indication, 2014 9
Daewoong Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2014 11
Daewoong Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2014 12
Daewoong Pharmaceutical Co., Ltd. - Combination Treatment Modalities in Pipeline, 2014 13
Daewoong Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2014 14
Daewoong Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 15
Daewoong Pharmaceutical Co., Ltd. - Pre-Registration, 2014 16
Daewoong Pharmaceutical Co., Ltd. - Phase III, 2014 17
Daewoong Pharmaceutical Co., Ltd. - Phase II, 2014 18
Daewoong Pharmaceutical Co., Ltd. - Phase I, 2014 19
Daewoong Pharmaceutical Co., Ltd. - Preclinical, 2014 20
Daewoong Pharmaceutical Co., Ltd. - Discovery, 2014 21
Daewoong Pharmaceutical Co., Ltd. - Unknown, 2014 22
Daewoong Pharmaceutical Co., Ltd. - Pipeline by Target, 2014 52
Daewoong Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2014 53
Daewoong Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2014 54
Daewoong Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2014 56
Daewoong Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2014 57
Daewoong Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2014 62
Daewoong Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2014 63
Daewoong Pharmaceutical Co., Ltd., Other Locations 65